Eli Lilly and Company appoints Sebastian Iovan General Manager for Romania Cluster. Sebastian Iovan will coordinate, starting July 1st, 2026, the company’s commercial, medical, and operational activity on the markets of Romania, Bulgaria, Serbia, Croatia, Slovenia, and Bosnia and Herzegovina.
Sebastian Iovan is a Medical Doctor from Cluj Napoca with a Master of Science in Health Economics from Bocconi University Milan, Italy and an MBA from IE Business School Madrid, Spain. Previously, Sebastian held the position of Vice President, Pricing, Reimbursement and Access (PRA) at Lilly China, playing a key role in ensuring the successful reimbursement of innovative medicine in type 2 diabetes and obesity management. Through strong cross-functional leadership, he shaped the strategic foundation and organizational readiness that expanded the availability of the company’s therapies to millions of patients in China.
“I am honored to take on this role and join a high-performing organization focused on innovation and patient care. For us, Romania is a relevant market, with potential, and the priority will be to improve patients’ access to innovative therapies, strengthen existing partnerships and support team development. I am confident that, starting from the solid foundation built by Attila, we will generate a positive impact for patients in Romania”, stated Sebastian Iovan.
“Sebastian has brought tremendous impact to Lilly China over the past several years. As the leader of PRA China, he has played a critical role in strengthening the organization’s access strategy & capability, advancing key business priorities, and helping the affiliate navigate a complex and evolving external environment”, stated Elias Khalil, President and General Manager of the Lilly Italy Hub.
Sebastian Iovan takes over from Attila Fejer, who will transition to the role of Senior Director, International Value & Access within the company. From July 1st, Attila Fejer will coordinate strategic international projects, continuing to make innovative medicines accessible to patients across the globe.
“Serving patients has been the defining thread of my entire professional life: from my training as a physician, to the fulfilling 11 years at the helm of Eli Lilly Romania – out of which the last year also as Cluster Manager. I am most grateful that during my mandate, together with my team of exceptional professionals, we made every innovation Lilly launched globally available to Romanian patients. I am also confident that Sebastian’s broad international experience and his constant commitment to improving patients’ lives will enable the organization to continue growing under his leadership”, stated Attila Fejer.
Eli Lilly and Company celebrates 150 years of history this year. In 2024, the company invested nearly $11 billion in R&D and provided access to its therapies for 58 million patients globally. In Romania, Lilly has been present since 1992 and has made available to patients over 30 innovative drugs in areas such as diabetes, obesity, oncology, and neurology.